Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 5,951 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Abstract Submission Deadline

The SOHO 2022 abstract submission deadline is June 1st! The SOHO scientific committee encourages all interested participants to attend the conference and to submit an abstract for publication in the Meeting Proceedings and for Poster Presentation.

Risk for Neurologic Adverse Events Less with Immune Checkpoint Inhibitors

The use of immune checkpoint inhibitors is associated with a decreased likelihood of developing neurologic adverse events compared with other cancer medications, particularly cytotoxic chemotherapy.

FDA Approves Axi-Cel as Initial Treatment for Relapsed, Refractory LBCL

The CAR T-cell therapy was approved for adults with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or that relapsed within 12 months of first-line treatment.

First Dose of Off-the-Shelf CAR T Given to Patients with R/R T-ALL/LBL

A phase 1/2 trial is currently underway to test the safety and tolerability of this therapy, the first off-the-shelf allogeneic CAR-T cell therapy targeting T-Cell malignancies used in the U.S.

Neurotoxicity Acceptable in CD19 CAR-T Cell Therapy for B-ALL with CNS Leukemia

CD19-directed CAR-T cell therapy could induce similar high response rates in patients with B-cell acute lymphoblastic leukemia with central nervous system leukemia.

IDH Mutation Location Affected Relapse Risk After AML Transplant

Certain IDH mutation locations had a higher association with risk of AML relapse after transplant.

hoelzer
"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top